ResMed

35 years ago, we made a promise to help people worldwide sleep, breathe and live better. Today, we continue to live up to that promise by developing digital health products and cloud-connected solutions that empower people to live happier, healthier, and higher quality lives from the comfort of their home. Thank you to the 10,000 ResMedians working worldwide to help impact the lives of people with sleep apnea, COPD, and other respiratory diseases and sleep disorders. And our deepest gratitude to those who've trusted us to improve their health and quality of life. Here's to the next 35 years! #ResMed35

While most people aim for 7-9 hours of sleep each night, quality sleep is also about how rejuvenated you feel in the morning. Our sleep cycle includes vital stages such as non-REM and REM sleep, each crucial for our well-being. 🔬 Dr. Sibasish Dey from ResMed explains that during deep sleep in the third stage of non-REM sleep, our bodies undergo significant physical restoration—repairing tissues, building muscle, and enhancing overall sleep quality. Learn more about deep sleep and get tips for improving quality sleep. https://lnkd.in/eEFiAUiz

📆 Diaries at the ready: we’ll be in Vienna from 8 to 10 September for #ERS2024.   Find our full programme here 👉 https://lnkd.in/gw5r-x9q As well as discussing the latest advances in respiratory medicine with healthcare professionals from all over the world 🌍 we’ll be hosting three scientific sessions – which we do hope you’ll join!  Our sessions provide an excellent opportunity to gain expert, practical insights into putting #patients at the centre of care – with a focus on personalising and optimising #OSA and #COPD treatment. European Respiratory Society

"ResMed has always done what’s best for patients, encouraging all patients to live healthier lives through sleep, diet and exercise. The recent SURMOUNT-OSA clinical trial results are good news for individuals with obesity and sleep apnea. GLP-1 medications will give physicians more options in how they treat patients; GLP-1s will likely be used concomitantly with positive airway pressure (PAP) therapy. " Our Chief Medical Officer, Carlos Nunez, takes a closer look at what the latest GLP-1 data could mean for those with OSA. https://lnkd.in/gKgdMjeT

"ResMed has always done what’s best for patients, encouraging all patients to live healthier lives through sleep, diet and exercise. The recent SURMOUNT-OSA clinical trial results are good news for individuals with obesity and sleep apnea. GLP-1 medications will give physicians more options in how they treat patients; GLP-1s will likely be used concomitantly with positive airway pressure (PAP) therapy. " Our Chief Medical Officer, Carlos Nunez, takes a closer look at what the latest GLP-1 data could mean for those with OSA. https://lnkd.in/gKgdMjeT

We’re thrilled to welcome 82 summer interns across North America to ResMed! As a market leader, we're committed to continuous learning, embracing new ideas, nurturing innovation, and inspiring creative solutions. We can't wait to see the incredible contributions you will make during your 12-week journey with us. Thank you for choosing to spend your summer at ResMed! To know more about our early careers program, check this out -- https://lnkd.in/gZd5BnzB #ResMed #ShapeTheFuture

This past week, we were excited to catch ResMed Chief Medical Officer, Carlos Nunez at HLTH Europe 2024 on the "Dream come true, or a neuro nightmare? Improving your sleep with digital solutions" panel. During the session, Carlos and the panel participants discussed topics such as the current state of sleep monitoring apps & relaxation tech and shared their thoughts on how technology as a whole can help mend our relationship with sleep. #HLTHEurope #HealthInnovation #HealthcareTransformation #DigitalHealth #HealthTech #CPAP #SleepHealth

"Our findings underscore the urgent need for enhanced clinical care pathways and policy interventions to effectively diagnose and treat insomnia. It is crucial to foster greater awareness of the critical role that sleep plays in overall health," - Adam Benjafield, Vice President, Medical Affairs, ResMed Read more about these important #sleephealth research findings coming out of the recent #SLEEP2024 Conference here from Medscape!

As a healthcare practitioner, researcher and someone who has spent much of my career focused on sleep health and conditions like obstructive sleep apnea (OSA) – a condition where obesity is an important risk factor – I am deeply interested in the use of GLP-1 medications for weight loss and the potential benefits that weight loss can have on sleep conditions. It’s especially top of mind for me as I make my way to the American Diabetes Association’s (ADA) Scientific Sessions later this week, where the full results from the SURMOUNT-OSA trial will be released. Without question, the most effective treatment for OSA has been and remains positive airway pressure (PAP) therapy, which has been proven to reduce the severity of sleep apnea by an average of 86% [1]. With that context, it’s important to note that the SURMOUNT-OSA trial was not designed to directly compare the effectiveness of the dual GLP-1/GIP receptor agonist tirzepatide to PAP therapy. Instead, it was designed to determine if use of tirzepatide for weight loss could reduce the apnea-hypopnea index (AHI) when compared with a placebo. By including patients using PAP therapy, the gold standard in OSA treatment, the trial provided information on combination use from a safety perspective [2]. It’s important to remember that weight loss alone may not be sufficient to eliminate OSA. Obesity is not the only risk factor for OSA, and we’ve seen that in >35% of cases where patients lose up to 50% of their body weight via interventions like bariatric surgery, clinically relevant sleep apnea remained present [3]. While we welcome any new advancements that get individuals more engaged in maintaining a healthy lifestyle, it’s important to continue to expand what we know about sleep health and how best to treat conditions like OSA. As clinicians, it’s incumbent upon us to help patients know and understand their risks for conditions like OSA, which can lower quality of life, increase the risk of many serious health conditions, and may even lead to death [4]. We must take this opportunity to raise awareness of the importance of sleep health and ensure that people at risk for sleep health challenges get screened, diagnosed and treated with the treatments that have the highest likelihood of reducing their risk of health complications. I’m looking forward to learning about the science that will be presented and the conversations I’ll have with colleagues at ADA's annual conference. There is so much more for us to talk about now that sleep health is getting more attention. There are 1 billion people with sleep apnea, and more than 80% are undiagnosed and untreated [5]. All of them deserve the chance to live their best, healthiest lives. *sources below in the comments*

What if unlocking the superpowers of restful sleep could help men live healthier, higher-quality lives?   This #InternationalMensHealthWeek, conquer your tiredness and start your journey to good sleep. Take a free sleep assessment today. https://lnkd.in/eC25VP92 #SleepPowers